» Articles » PMID: 28160569

Mitotic Cell Death Induction by Targeting the Mitotic Spindle with Tubulin-inhibitory Indole Derivative Molecules

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Feb 5
PMID 28160569
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Tubulin-targeting molecules are widely used cancer therapeutic agents. They inhibit microtubule-based structures, including the mitotic spindle, ultimately preventing cell division. The final fates of microtubule-inhibited cells are however often heterogeneous and difficult to predict. While recent work has provided insight into the cell response to inhibitors of microtubule dynamics (taxanes), the cell response to tubulin polymerization inhibitors remains less well characterized. Arylthioindoles (ATIs) are recently developed tubulin inhibitors. We previously identified ATI members that effectively inhibit tubulin polymerization in vitro and cancer cell growth in bulk cell viability assays. Here we characterise in depth the response of cancer cell lines to five selected ATIs. We find that all ATIs arrest mitotic progression, yet subsequently yield distinct cell fate profiles in time-lapse recording assays, indicating that molecules endowed with similar tubulin polymerization inhibitory activity in vitro can in fact display differential efficacy in living cells. Individual ATIs induce cytological phenotypes of increasing severity in terms of damage to the mitotic apparatus. That differentially triggers MCL-1 down-regulation and caspase-3 activation, and underlies the terminal fate of treated cells. Collectively, these results contribute to define the cell response to tubulin inhibitors and pinpoint potentially valuable molecules that can increase the molecular diversity of tubulin-targeting agents.

Citing Articles

A Novel Pyrazole Exhibits Potent Anticancer Cytotoxicity via Apoptosis, Cell Cycle Arrest, and the Inhibition of Tubulin Polymerization in Triple-Negative Breast Cancer Cells.

Borrego E, Guerena C, Schiaffino Bustamante A, Gutierrez D, Valenzuela C, Betancourt A Cells. 2024; 13(14.

PMID: 39056806 PMC: 11274517. DOI: 10.3390/cells13141225.


Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia.

Cairns L, Lappin K, Mutch A, Ali A, Matchett K, Mills K Int J Mol Sci. 2021; 22(18).

PMID: 34576326 PMC: 8468645. DOI: 10.3390/ijms221810163.


Intracellular Signaling Responses Induced by Radiation within an In Vitro Bone Metastasis Model after Pre-Treatment with an Estrone Analogue.

Helena J, Joubert A, Mabeta P, Coetzee M, Lakier R, Mercier A Cells. 2021; 10(8).

PMID: 34440874 PMC: 8394480. DOI: 10.3390/cells10082105.


Non-linear Dose Response of Lymphocyte Cell Lines to Microtubule Inhibitors.

Potashnikova D, Saidova A, Tvorogova A, Sheval E, Vorobjev I Front Pharmacol. 2019; 10:436.

PMID: 31068822 PMC: 6491834. DOI: 10.3389/fphar.2019.00436.


Single-Cell Tracking of A549 Lung Cancer Cells Exposed to a Marine Toxin Reveals Correlations in Pedigree Tree Profiles.

Korsnes M, Korsnes R Front Oncol. 2018; 8:260.

PMID: 30023341 PMC: 6039982. DOI: 10.3389/fonc.2018.00260.

References
1.
Pasquier E, Kavallaris M . Microtubules: a dynamic target in cancer therapy. IUBMB Life. 2008; 60(3):165-70. DOI: 10.1002/iub.25. View

2.
Massarotti A, Coluccia A, Silvestri R, Sorba G, Brancale A . The tubulin colchicine domain: a molecular modeling perspective. ChemMedChem. 2011; 7(1):33-42. DOI: 10.1002/cmdc.201100361. View

3.
Perez E . Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009; 8(8):2086-95. DOI: 10.1158/1535-7163.MCT-09-0366. View

4.
Neumann B, Walter T, Heriche J, Bulkescher J, Erfle H, Conrad C . Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature. 2010; 464(7289):721-7. PMC: 3108885. DOI: 10.1038/nature08869. View

5.
Weaver B . How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014; 25(18):2677-81. PMC: 4161504. DOI: 10.1091/mbc.E14-04-0916. View